Registration for a live webinar on 'Chronic inflammation, immune cell trafficking and anti-trafficking agents' is now open.See webinar details
Polymyalgia rheumatica: causes, symptoms, diagnosis, treatment, and outlook
Published on February 28, 2023 43 min
A selection of talks on Immunology
Inflammation: purposes, mechanisms and development
- Prof. Pietro Ghezzi
- University of Urbino, Italy
Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
- Deutsches Rheuma-Forschungszentrum, Germany
It gives me great pleasure to talk to you about polymyalgia rheumatica, the causes of PMR symptoms, the diagnosis, treatment, and the outlook of the condition.
Here are my disclosures.
This is the evidence base for the talk. Primarily, it includes the BSR guidelines on PMR published back in 2010. The 2012 EULAR ACR classification criteria for PMR, published in 2012. The patient-reported outcomes in PMR. The clinical outcomes, quality of life and diagnostic uncertainty in PMR. The PMR UK outcome study, which was completed back in 2006. And of course the 2015 EULAR ACR PMR recommendations. I shall also cite recent papers about the pathophysiology of PMR based on the work that has come out of Groningen in the Netherlands.
The areas that will be covered in my talk: one, the pathophysiology, two, the approach that we take to PMR as well as the polymyalgic syndrome. We will talk in detail about the 2015 EULAR ACR and 2009 BSR recommendations. We'll talk about the overarching principles, indications for early specialist referral, the role of disability and quality of life in PMR. How do we assess PMR? How do we treat PMR with glucocorticoids, initial dosage and glucocorticoid taper? Whether there's a role for disease-modifying agents such as methotrexate, leflunomide, and the increasing scope of biologics in PMR. The role of lifestyle measures such as exercise and, of course, we will talk a little bit about some of the clinical trials that are going on.